Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyBiologicalProcessrRNA processing

DDX51 NOP53

2.51e-0323072GO:0006364
CytobandEnsembl 112 genes in cytogenetic band chr22q12

ZNRF3 TUG1

1.14e-03235102chr22q12
CoexpressionGSE41176_WT_VS_TAK1_KO_UNSTIM_BCELL_UP

NRTN C10orf95 NOP53

3.45e-0519893M9921
ToppCellMild/Remission-B_naive-1|World / disease group and sub_cluster of B and Plasma cells(res = 0.5)

TUG1 NOP53

3.18e-0412110268940a552233d255b90ce5a081339c0d9d46ab02
ToppCellMild/Remission-B_intermediate-1|Mild/Remission / disease group and sub_cluster of B and Plasma cells(res = 0.5)

TUG1 NOP53

3.29e-0412310269b7f2f4604bf221a0ff581c51de743e8a4c0537
ToppCellSevere-B_intermediate-1|Severe / disease group and sub_cluster of B and Plasma cells(res = 0.5)

TUG1 NOP53

3.45e-0412610242a0bdbe18ef85146cac4e86b2b27d0b3b20d8a2
ToppCellSevere-B_naive-1|World / disease group and sub_cluster of B and Plasma cells(res = 0.5)

TUG1 NOP53

4.26e-04140102683ee5e103f0c68cbbec019249404d381dbc39f3
ToppCellMild/Remission-B_naive-1|Mild/Remission / disease group and sub_cluster of B and Plasma cells(res = 0.5)

TUG1 NOP53

4.44e-04143102bd3f5fbd4e9e4dc414682db5607494f3ce988deb
ToppCellprimary_visual_cortex-Neuronal-glutamatergic_neuron-L5_IT-L5_IT_VISp_Whrn_Tox2|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype

ADRA1D FOXL3

4.44e-0414310236ce6f163fb33141c86288086c354b91853fad25
ToppCellControl-B_intermediate-1|World / disease group and sub_cluster of B and Plasma cells(res = 0.5)

TUG1 NOP53

4.50e-04144102984470ff6ddce4c743e2db78fa98dae055aaa273
ToppCellPBMC-Severe-cDC_8|Severe / Compartment, Disease Groups and Clusters

DDX51 NRTN

4.56e-0414510223a9a4fd1934c4a38d9259105c1fdbac459575cb
ToppCellControl-B_naive-1|World / disease group and sub_cluster of B and Plasma cells(res = 0.5)

TUG1 NOP53

5.21e-041551020a78d1cab2bdba2dc8a74cdf35b5a0192370c4b5
ToppCell368C-Myeloid-Monocyte-CD16+_Monocyte|368C / Donor, Lineage, Cell class and subclass (all cells)

DDX51 C10orf95

5.28e-0415610225b0936960be4955b6a6d6b8a867fdd4be548f05
ToppCellSevere-B_naive-1|Severe / disease group and sub_cluster of B and Plasma cells(res = 0.5)

TUG1 NOP53

5.48e-041591022881b054bbeb479221ee3c38bbd9b0815b123579
ToppCellPBMC-Severe-Lymphocyte-B-B_cell-B_naive-B_naive-1|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

TUG1 NOP53

5.90e-04165102fead3f2032f8fa5f7f0159a4434989b3d65debbb
ToppCellCOVID-19_Mild-Classical_Monocyte-cMono_1|COVID-19_Mild / Disease condition and Cell class

TUG1 NOP53

5.90e-04165102ef709c5d3231c65d351316e1e31b9c9eba721628
ToppCell368C-Myeloid-Monocyte-CD16+_Monocyte|Myeloid / Donor, Lineage, Cell class and subclass (all cells)

DDX51 C10orf95

6.04e-04167102dbd2b9f2f4ba7be5fdf8318094e6b078cb1d1c43
ToppCellControl-B_intermediate-1|Control / disease group and sub_cluster of B and Plasma cells(res = 0.5)

TUG1 NOP53

6.04e-04167102948504367ecf58144d9dd74d2ec531358fc4b309
ToppCellCOVID-19_Mild-Classical_Monocyte-cMono_1|Classical_Monocyte / Disease condition and Cell class

TUG1 NOP53

6.12e-04168102d50078614f7af74dc2aa4081c1708a5156ac51cf
ToppCellControl-B_naive-1|Control / disease group and sub_cluster of B and Plasma cells(res = 0.5)

TUG1 NOP53

6.33e-04171102d18855b24aadea38fd1e4592f945cf15b85e05f1
ToppCell5'-Airway_Nasal-Epithelial-Airway_epithelium-respiratory_basal_cell-Suprabasal-|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

SRRM3 NRTN

6.33e-04171102121e63ca281ad765d76c2afb3b4d441329b47f81
ToppCellCOVID-19_Severe-Classical_Monocyte-cMono_1|Classical_Monocyte / Disease condition and Cell class

TUG1 NOP53

6.63e-0417510235ea2ed93538e6bf803029fcf7d9243f93e7733d
ToppCellPBMC-Mild-Lymphocyte-T/NK-NK_cell-NK_activated-|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

TUG1 NOP53

6.78e-04177102d3e6c768b88b7906f3c7fdd00ba20842212c14b1
ToppCellPBMC-Mild-Lymphocyte-T/NK-NK_cell-NK_activated|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09)

TUG1 NOP53

6.78e-04177102936ab2b180a052387124f68d0c7f41c0b164e748
ToppCellPBMC-Mild-Lymphocyte-T/NK-NK_cell-NK_activated|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

TUG1 NOP53

6.78e-04177102f8f101c772c043636bedd6b2ec81409b1d2599bf
ToppCellPBMC-Mild-Lymphocyte-T/NK-NK_cell-NK_activated-|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)

TUG1 NOP53

6.78e-04177102d5aeda113afaa2425874394610344570c9078478
ToppCellCOVID-19_Mild-Lymphoid_T/NK-NK_activated|COVID-19_Mild / Disease group, lineage and cell class

TUG1 NOP53

6.78e-041771026978a22fef40c8b455342373abe7593f5ede0fa4
ToppCelldroplet-Lung-immune-endo-depleted-3m-Mesenchymal-Pericyte|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

ADRA1D SRRM3

7.01e-0418010240a28b410f46215d6d7cf8a02a18078eb046b5b0
ToppCelldroplet-Lung-immune-endo-depleted-3m-Mesenchymal-pericyte_cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

ADRA1D SRRM3

7.01e-041801020153667e44fdbc3c0d444dcb023069925a2b69a2
ToppCellCOVID-19_Severe-Classical_Monocyte-cMono_1|COVID-19_Severe / Disease condition and Cell class

TUG1 NOP53

7.09e-041811020d07a67e8ee3bca687b378afbc4044434e63556d
ToppCellCOVID-19_Mild-CD4+_T_activated|COVID-19_Mild / Disease condition and Cell class

TUG1 NOP53

7.17e-04182102877b6e611626628e709568747512f2827ebb2795
ToppCellPBMC-Mild-Lymphocyte-T/NK-CD4+_T-CD4+_T_activated|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09)

TUG1 NOP53

7.17e-041821021aea96ee211f7b9caef7fd385233f51be6021a73
ToppCellPBMC-Mild-Lymphocyte-T/NK-CD4+_T-CD4+_T_activated|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

TUG1 NOP53

7.17e-041821024cb182ef39be2044a6ad7266f332d4177591e550
ToppCellPBMC-Mild-Lymphocyte-T/NK-CD4+_T-CD4+_T_activated-|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

TUG1 NOP53

7.17e-04182102c0f63cfc67d61c0877b7acb2946dfb35aae8a8f5
ToppCellPBMC-Mild-Lymphocyte-T/NK-CD4+_T-CD4+_T_activated-|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)

TUG1 NOP53

7.17e-04182102b427e43ee523a3ea9eca3207f3d82042f10f022a
ToppCellCOVID-19_Mild-Lymphoid_T/NK-CD4+_T_activated|COVID-19_Mild / Disease group, lineage and cell class

TUG1 NOP53

7.25e-041831027717fce227b4e02ed41baad8ae7dd2e22bd7c13e
ToppCellCOVID-19_Mild-NK_activated|COVID-19_Mild / Disease condition and Cell class

TUG1 NOP53

7.25e-0418310222bd05135906d0ecc4ba8c2e0a666093d1bf3b8f
ToppCelldroplet-Lung-1m-Mesenchymal-myofibroblast-pericyte_cell-pericyte|1m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

ADRA1D NRTN

7.33e-041841024cb5f299dd7413e0be1ad7af817ee614b23a18ae
ToppCelldroplet-Lung-1m-Mesenchymal-myofibroblast-pericyte_cell|1m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

ADRA1D NRTN

7.33e-0418410239bb0eb55bdc2cea46e41c7f21d8c5883f14e6bd
ToppCellfacs-Lung-EPCAM-18m-Mesenchymal-Myofibroblast|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

ADRA1D NRTN

7.48e-04186102ecc5acd111a6ee50d59544d1bdd7ed94e2812aae
ToppCellfacs-Lung-EPCAM-18m-Mesenchymal-pulmonary_interstitial_fibroblast|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

ADRA1D NRTN

7.48e-04186102aa88d9573a237b2b8e6025fee31f69fbce824497
ToppCellfacs-Lung-18m-Mesenchymal-myofibroblast-myofibroblast_cell|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

ADRA1D NRTN

7.48e-0418610226458ff8cad5577de4306cffa0ca69eb26940e0d
ToppCellfacs-Lung-18m-Mesenchymal-myofibroblast-myofibroblast_cell-pulmonary_interstitial_myofibroblast|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

ADRA1D NRTN

7.48e-04186102a71397efc68d2916ddc373d92cfd07be58033e1c
ToppCelldroplet-Lung-18m-Mesenchymal-myofibroblast-tracheobronchial_smooth_muscle_cell-smooth_muscle_cell_of_trachea_l39|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

ADRA1D NRTN

7.56e-04187102218c9b4f28499389c43005d9626af2ac01066027
ToppCelldroplet-Lung-18m-Mesenchymal-myofibroblast-tracheobronchial_smooth_muscle_cell|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

ADRA1D NRTN

7.56e-04187102c7ac4b328efc2ebb72f71154661914193ff402ca
ToppCelldroplet-Lung-nan-18m-Mesenchymal-bronchial_smooth_muscle_cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

ADRA1D NRTN

7.65e-041881027553ef7de3575af4cf34704b405b551c1af8eb83
ToppCelldroplet-Lung-nan-18m-Mesenchymal-Airway_Smooth_Muscle|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

ADRA1D NRTN

7.65e-0418810261f010c165826b434ca3d27553d4c9e13d2c0c51
ToppCelldroplet-Lung-1m-Mesenchymal-myofibroblast|1m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

ADRA1D NRTN

7.97e-04192102dc4b4e16e6eb212e45fb70695afd1c7e91027407
ToppCellsystemic_lupus_erythematosus-managed-Lymphocytic_T-CD4-positive,_alpha-beta_T_cell-male|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex

ADRA1D NOP53

8.22e-04195102003a104daf88ea46fb6c7284f61cc3a02d0311e8
ToppCellTracheal-10x5prime-Stromal-Fibroblastic-Fibro_immune_recruiting|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations

WWC2-AS2 SRRM3

8.64e-04200102f692b602bc989d35c9162e73dda813dbef8d5267
DrugBenzethonium chloride [121-54-0]; Up 200; 9uM; MCF7; HT_HG-U133A

ADRA1D C10orf95

2.28e-03185927207_UP
DrugMethimazole [60-56-0]; Down 200; 35uM; PC3; HT_HG-U133A

DDX51 ADRA1D

2.42e-03191923815_DN
DrugIsoquinoline, 6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydro, hydrochloride; Up 200; 16.4uM; MCF7; HT_HG-U133A

DDX51 ADRA1D

2.42e-03191922824_UP
DrugAsiaticoside [16830-15-2]; Up 200; 4.2uM; MCF7; HT_HG-U133A

ADRA1D C10orf95

2.45e-03192927004_UP
DrugGlimepiride [93479-97-1]; Up 200; 8.2uM; PC3; HT_HG-U133A

NRTN C10orf95

2.50e-03194926628_UP
DrugDipyrone [5907-38-0]; Down 200; 12uM; MCF7; HT_HG-U133A

ADRA1D C10orf95

2.53e-03195923835_DN
DrugDipyridamole [58-32-2]; Up 200; 8uM; MCF7; HT_HG-U133A

ADRA1D C10orf95

2.53e-03195921517_UP
DrugHydrastinine hydrochloride [4884-68-8]; Down 200; 16.4uM; MCF7; HT_HG-U133A

DDX51 ADRA1D

2.53e-03195922283_DN
DrugPirenperone [ 75444-65-4]; Down 200; 10.2uM; MCF7; HT_HG-U133A

ADRA1D C10orf95

2.55e-03196925639_DN
DrugIndapamide [26807-65-8]; Up 200; 10.6uM; MCF7; HT_HG-U133A

DDX51 ADRA1D

2.55e-03196922322_UP
DrugPempidine tartrate [546-48-5]; Down 200; 13uM; MCF7; HT_HG-U133A

ADRA1D C10orf95

2.55e-03196923832_DN
DrugNorgestrel-(-)-D [797-63-7]; Up 200; 12.8uM; HL60; HT_HG-U133A

DDX51 ADRA1D

2.55e-03196922547_UP
DrugEdrophonium chloride [116-38-1]; Up 200; 19.8uM; PC3; HT_HG-U133A

DDX51 ADRA1D

2.55e-03196926655_UP
DrugResveratrol [501-36-0]; Up 200; 17.6uM; PC3; HT_HG-U133A

DDX51 NRTN

2.55e-03196925084_UP
DrugEtilefrine hydrochloride [534-87-2]; Down 200; 18.4uM; PC3; HT_HG-U133A

DDX51 ADRA1D

2.55e-03196924590_DN
DrugEstriol [50-27-1]; Up 200; 13.8uM; MCF7; HT_HG-U133A

ADRA1D C10orf95

2.55e-03196923563_UP
DrugSolasodine [126-17-0]; Down 200; 9.6uM; MCF7; HT_HG-U133A

ADRA1D C10orf95

2.55e-03196923830_DN
DrugEpiandrosterone [481-29-8]; Down 200; 13.8uM; MCF7; HT_HG-U133A

NRTN C10orf95

2.55e-03196923306_DN
DrugTimolol maleate salt [26921-17-5]; Down 200; 9.2uM; MCF7; HT_HG-U133A

ADRA1D C10orf95

2.55e-03196926483_DN
DrugMethiazole; Down 200; 15uM; PC3; HT_HG-U133A

DDX51 ADRA1D

2.55e-03196923796_DN
DrugMethoxy-8-psoralen [298-81-7]; Down 200; 18.6uM; MCF7; HT_HG-U133A

NRTN C10orf95

2.55e-03196923302_DN
DrugRaloxifene hydrochloride [82640-04-8]; Down 200; 7.8uM; PC3; HT_HG-U133A

ADRA1D NRTN

2.55e-03196925759_DN
DrugSulpiride [15676-16-1]; Up 200; 11.8uM; MCF7; HT_HG-U133A

DDX51 C10orf95

2.58e-03197921467_UP
Drug6-Furfurylaminopurine [525-79-1]; Down 200; 18.6uM; PC3; HT_HG-U133A

ADRA1D NRTN

2.58e-03197924477_DN
DrugChlorhexidine [55-56-1]; Up 200; 8uM; MCF7; HT_HG-U133A

NRTN C10orf95

2.58e-03197925403_UP
DrugMyricetin [529-44-2]; Down 200; 12.6uM; MCF7; HT_HG-U133A

DDX51 C10orf95

2.58e-03197923270_DN
DrugStachydrine hydrochloride; Up 200; 22.2uM; MCF7; HT_HG-U133A

NRTN C10orf95

2.58e-03197922743_UP
DrugAmoxapine [14028-44-5]; Up 200; 12.8uM; MCF7; HT_HG-U133A

ADRA1D C10orf95

2.58e-03197921513_UP
DrugFludrocortisone acetate [514-36-3]; Down 200; 9.4uM; MCF7; HT_HG-U133A

ADRA1D C10orf95

2.58e-03197922328_DN
DrugDicyclomine hydrochloride [67-92-5]; Down 200; 11.6uM; MCF7; HT_HG-U133A

DDX51 C10orf95

2.58e-03197924405_DN
DrugPropafenone hydrochloride [34183-22-7]; Down 200; 10.6uM; MCF7; HT_HG-U133A

ADRA1D C10orf95

2.58e-03197925437_DN
Drugestradiol, USP; Up 200; 0.01uM; PC3; HT_HG-U133A

DDX51 ADRA1D

2.58e-03197924465_UP
DrugCyclizine hydrochloride [303-25-3]; Up 200; 13.2uM; MCF7; HT_HG-U133A

NRTN C10orf95

2.58e-03197922880_UP
Drughaloperidol; Up 200; 10uM; MCF7; HT_HG-U133A

ADRA1D NRTN

2.58e-03197927003_UP
DrugYohimbinic acid monohydrate [27801-27-2]; Up 200; 11.2uM; MCF7; HT_HG-U133A

DDX51 NRTN

2.58e-03197922803_UP
DrugAmiodarone hydrochloride [19774-82-4]; Up 200; 5.8uM; MCF7; HT_HG-U133A

DDX51 C10orf95

2.58e-03197925618_UP
DrugN-Acetyl-DL-homocysteine Thiolactone [1195-16-0]; Down 200; 25.2uM; MCF7; HT_HG-U133A

ADRA1D C10orf95

2.58e-03197923836_DN
DrugCP-320650-01 [172079-28-6]; Down 200; 1uM; MCF7; HT_HG-U133A

DDX51 NRTN

2.58e-03197924382_DN
Drug(+)-Isoproterenol (+)-bitartrate salt [14638-70-1]; Up 200; 11uM; MCF7; HT_HG-U133A

ADRA1D C10orf95

2.58e-03197925009_UP
DrugTheobromine [83-67-0]; Down 200; 22.2uM; MCF7; HT_HG-U133A

ADRA1D C10orf95

2.58e-03197923334_DN
DrugSulfamethoxazole [723-46-6]; Up 200; 15.8uM; MCF7; HT_HG-U133A

DDX51 C10orf95

2.58e-03197924690_UP
DrugFosfosal [6064-83-1]; Up 200; 18.4uM; PC3; HT_HG-U133A

DDX51 ADRA1D

2.58e-03197924239_UP
DrugMeprylcaine hydrochloride [956-03-6]; Up 200; 14.8uM; PC3; HT_HG-U133A

DDX51 ADRA1D

2.60e-03198925723_UP
DrugAzathioprine [446-86-6]; Down 200; 14.4uM; MCF7; HT_HG-U133A

ADRA1D C10orf95

2.60e-03198925627_DN
DrugMyosmine [532-12-7]; Up 200; 27.4uM; PC3; HT_HG-U133A

NRTN C10orf95

2.60e-03198924293_UP
DrugTiaprofenic acid [33005-95-7]; Up 200; 15.4uM; MCF7; HT_HG-U133A

NRTN C10orf95

2.60e-03198924171_UP
DrugTocainide hydrochloride; Down 200; 17.4uM; MCF7; HT_HG-U133A

ADRA1D C10orf95

2.60e-03198924838_DN
DrugDimethisoquin hydrochloride [2773-92-4]; Down 200; 13uM; MCF7; HT_HG-U133A

NRTN C10orf95

2.60e-03198924791_DN
DrugPiperacillin sodium salt [59703-84-3]; Up 200; 7.4uM; PC3; HT_HG-U133A

DDX51 ADRA1D

2.60e-03198924320_UP
DrugVitamin K2 [11032-49-8]; Down 200; 9uM; MCF7; HT_HG-U133A

DDX51 C10orf95

2.60e-03198924356_DN
DrugParomomycin sulfate [1263-89-4]; Down 200; 5.6uM; MCF7; HT_HG-U133A

ADRA1D C10orf95

2.60e-03198923356_DN
DrugParomomycin sulfate [1263-89-4]; Down 200; 5.6uM; PC3; HT_HG-U133A

DDX51 NRTN

2.60e-03198924595_DN
DrugProbucol [23288-49-5]; Up 200; 7.8uM; MCF7; HT_HG-U133A

NRTN C10orf95

2.60e-03198923223_UP
DrugPepstatin A [26305-03-3]; Down 200; 5.8uM; MCF7; HT_HG-U133A

NRTN C10orf95

2.60e-03198924790_DN
DrugProparacaine hydrochloride [5875-06-9]; Down 200; 12uM; MCF7; HT_HG-U133A

ADRA1D C10orf95

2.60e-03198925433_DN
DrugDinoprost trometamol [38362-01-5]; Up 200; 8.4uM; MCF7; HT_HG-U133A

NRTN C10orf95

2.60e-03198925409_UP
DrugClozapine [5786-21-0]; Up 200; 12.2uM; MCF7; HT_HG-U133A

ADRA1D C10orf95

2.60e-03198922644_UP
DrugArcaine sulfate [14923-17-2]; Up 200; 14.8uM; PC3; HT_HG-U133A

NRTN C10orf95

2.63e-03199926629_UP
Drug(S)-(-)-Cycloserine [339-72-0]; Down 200; 39.2uM; MCF7; HT_HG-U133A

DDX51 ADRA1D

2.63e-03199924346_DN
DrugGliquidone [33342-05-1]; Up 200; 7.6uM; MCF7; HT_HG-U133A

DDX51 C10orf95

2.63e-03199926004_UP
DrugGanciclovir [82410-32-0]; Up 200; 15.6uM; MCF7; HT_HG-U133A

DDX51 C10orf95

2.63e-03199925389_UP
DrugXylometazoline hydrochloride [1218-35-5]; Up 200; 14.2uM; MCF7; HT_HG-U133A

ADRA1D C10orf95

2.63e-03199927020_UP

Protein segments in the cluster

PeptideGeneStartEntry
PRRRSRSPRRRDRGR

PRPF4B

461

Q13523
PGPRRRAGPRRRRAR

NRTN

81

Q99748
RRRRGPRNKKRGWRR

NOP53

36

Q9NZM5
EPATRRRRRPRRRRR

DDX51

61

Q8N8A6
RRRRRRRGPKREGPR

FOXL3

126

A0A1W2PRP0
GGAGRRRRRRRRRRR

SRRM3

381

A6NNA2
CRRRRRRRPLWRVYG

ADRA1D

421

P25100
RRPRRWPRAGRRGRR

C10orf95

146

Q9H7T3
RPPRRAPGGRWRSRR

TUG1

41

A0A6I8PU40
ATGRRRRRLRRRPRG

ZNRF3

11

Q9ULT6
ARRCGRPRRRDPRRR

WWC2-AS2

86

Q96NR7